Pharmacokinetics and metabolomics of the new psychoactive substance 4-chloroethylcathinone

被引:4
|
作者
Wang, Yong [1 ,2 ]
Yang, Ying [3 ]
Zhan, Yujuan [3 ]
Yin, Jun [3 ]
Zhou, Xueting [3 ]
Xu, Chen [3 ]
Gao, Feiyu [3 ]
Liu, Junning [2 ]
Wu, Chunyong [3 ]
Liu, Songqin [1 ]
Zhang, Junying [4 ]
Shu, Chang [3 ]
机构
[1] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Peoples R China
[2] Nanjing Publ Secur Bur, Inst Forens Sci & Technol, Nanjing 210001, Peoples R China
[3] China Pharmaceut Univ, Dept Pharmaceut Anal, Nanjing 211198, Peoples R China
[4] China Pharmaceut Univ, Dept Tradit Chinese Med, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
4-Chloroethylcathinone; New psychoactive substance; Pharmacokinetics; Untargeted metabolomics; MICE;
D O I
10.1016/j.arabjc.2023.105039
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Synthetic 4-Chloroethcathinone (4-CEC) is a derivative of cathinone that belongs to one of the more severe abused substances among new psychoactive substances (NPS). Current researches on 4-CEC mainly focus on metabolite identification studies, and there is a lack of researches on phar-macokinetic, tissue distribution and metabolomics studies in vivo. A sensitive and reliable LC-MS/ MS assay was developed and validated for the determination of 4-CEC concentrations in plasma and tissue homogenates. According to the pharmacokinetic results, the absorption and elimination of 4-CEC were faster after administration. The Cmax was 1896 & PLUSMN; 876 ng/ml, the peak time Tmax was 10.1 & PLUSMN; 9.2 min, and the elimination half-life t1/2 was 100.4 min. Metabolomics studies showed that the highest concentrations of 4-CEC were found in brain, lung, kidney and liver. The results of tissue biopsy showed that the liver, kidney and brain tissue had a certain degree of damage. After 4-CEC administration, amino acid-related metabolism and biosynthesis, lipid metabolism, niacin and niaci-namide metabolism in mice were interfered, suggesting that 4-CEC could cause energy metabolism disorder in mice. The metabolic pathways and toxicity mechanisms related to 4-CEC entry into the body were explained at the overall metabolic level by multivariate data analysis, screening and iden-tification of differential metabolites and metabolic pathway analysis.& COPY; 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment
    Sanches Moraes, Barbra Katyuschya
    Bajerski, Lisiane
    Parisotto, Alcides
    da Rosa Silva, Carlos Eduardo
    Alves, Marina Amaral
    Barreiro, Eliezer de Jesus
    Freddo, Rodrigo Jose
    Dalla Costa, Teresa
    Lima, Lidia Moreira
    Haas, Sandra Elisa
    BIOMEDICAL CHROMATOGRAPHY, 2016, 30 (07) : 1029 - 1035
  • [42] Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]platinum(II) in dogs
    Kim, DK
    Cho, YB
    Kim, HT
    Kim, TS
    Kim, KH
    Hong, WS
    ANTICANCER RESEARCH, 1996, 16 (3A) : 1167 - 1169
  • [43] In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane]platinum(II)
    Kim, DK
    Kim, HT
    Cho, YB
    Kim, TS
    Kim, KH
    Hong, WS
    ANTICANCER RESEARCH, 1996, 16 (01) : 251 - 256
  • [44] PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF A NEW PLATINUM COMPOUND, CIS-MALONATO[(4R,5R) 4,5-BIS(AMINOMETHYL)-2-ISOPROPYL-1, 3-DIOXOLANE]PRATINUM(II), AS DETERMINED BY EX-VIVO PHARMACODYNAMICS
    KIM, DK
    KIM, HT
    TAI, JH
    CHO, YB
    KIM, TS
    KIM, KH
    PARK, JG
    HONG, WS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 37 (1-2) : 1 - 6
  • [45] Pharmacokinetics, biodistribution and toxicology following intravenous and oral administration of DSM-RX78 and EFB-1, two new 2-(2-fluorobenzamido)benzoate-based PDE4 inhibitors, to rats
    Fang, Jia-You
    Liu, Yi-Ting
    Huang, Yaw-Bin
    Pan, Tai-Long
    Wang, Han-Hsiang
    Hsieh, Pei-Wen
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2013, 65 (03) : 345 - 354
  • [46] Pharmacokinetics of a new antitumor agent, 1-[3-(furo[3,2-c]quinolin-4-ylamino)phenyl]-ethanoe-O-methyl-oxime, in rat using a high performance liquid chromatography method
    Wu, PC
    Huang, YB
    Chang, CK
    Chen, YL
    Tzeng, CC
    Tsai, YH
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2005, 13 (01) : 38 - 42
  • [47] Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6-and 8-mm needles accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males
    Hirose, Takahisa
    Ogihara, Takeshi
    Tozaka, Shusaku
    Kanderian, Sami
    Watada, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (03) : 287 - 296
  • [48] Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats, new adriamycin analogues containing fluorine
    Yoon, EJ
    Lee, WI
    Shim, HJ
    Lee, SD
    Kim, WB
    Yang, JN
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1996, 17 (05) : 373 - 420
  • [49] PHARMACOKINETICS AND PLASMA-PROTEIN BINDING OF THE NEW POTENT CLASS-III ANTIARRHYTHMIC AGENT 3-[4-(1H-IMADAZOL-1-YL)BENZOYL]-7-ISOPROPYL-3,7-DIAZABICYCLO[3.3.1]NONANE DIHYDROPERCHLORATE
    CHEN, CL
    SANGIAH, S
    RODER, JD
    CHEN, H
    BERLIN, KD
    GARRISON, GL
    SCHERLAG, BJ
    LAZZARA, R
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1995, 45-1 (06): : 670 - 675
  • [50] SEX-DIFFERENCES IN THE DISPOSITION OF SUBSTITUTED BENZAMIDES - PHARMACOKINETICS OF A GASTROPROKINETIC AGENT (4-AMINO-5-CHLORO-2-[2-(METHYLSULFINYL) ETHOXY]-N-[2-(DIETHYLAMINO)ETHYL] BENZAMIDE HYDROCHLORIDE) (ML-1035) IN MALE AND FEMALE NEW-ZEALAND WHITE-RABBITS
    RAO, N
    OTIS, KW
    HWANG, KK
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (09) : 681 - 691